Solanezumab

CAS No. 955085-14-0

Solanezumab( —— )

Catalog No. M36734 CAS No. 955085-14-0

Solanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 613 In Stock
10MG 938 In Stock
25MG 1454 In Stock
50MG 1841 In Stock
100MG 2595 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Solanezumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Solanezumab (LY 2062430) is a monoclonal antibody that binds preferentially to soluble amyloid and promotes its clearance from the brain.Solanezumab is used in the study of Alzheimer's disease.
  • Description
    Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Beta Amyloid
  • Recptor
    Beta Amyloid
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    955085-14-0
  • Formula Weight
    144.1 (kDa)
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Honig LS, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018 Jan 25;378(4):321-330.?
molnova catalog
related products
  • Amyloid β Peptide (4...

    Amyloid β-Peptide (1-42) human is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.

  • Lecanemab

    Lecanemab (BAN-2401) is an IgG1 monoclonal antibody targeting soluble aggregated β-amyloid (Abeta) with activity against oligomers, protofibrils, and insoluble protofibrils, and may be useful in the study of Alzheimer's disease (AD)-induced mild cognitive impairment and mild AD dementia.

  • GRGDSPK acetate

    GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.